Literature DB >> 11999140

Cardiovascular properties of the kallikrein-kinin system.

Jagdish N Sharma1, Jyoti Sharma.   

Abstract

All the components of the kallikrein-kinin system are located in the vascular smooth muscle as well as in the heart. In recent years, numerous observations obtained from clinical and experimental models of diabetes, hypertension, cardiac failure, ischaemia, myocardial infarction and left ventricular hypertrophy, have suggested that the reduced activity of the local kallikrein-kinin system may be instrumental in the induction of cardiovascular-related diseases. The ability of kallikrein gene delivery to produce a wide spectrum of beneficial effects makes it an excellent candidate in treating hypertension, and cardiovascular and renal diseases. In addition, stable kinin agonists may also be available in the future as therapeutic agents for cardiovascular and renal disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11999140     DOI: 10.1185/03007990212500093

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  5 in total

Review 1.  The kallikrein-kinin system: from mediator of inflammation to modulator of cardioprotection.

Authors:  Jagdish N Sharma
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

Review 2.  [Pathophysiology of chronic heart failure].

Authors:  Joachim Weil; Heribert Schunkert
Journal:  Clin Res Cardiol       Date:  2006       Impact factor: 5.460

Review 3.  The kinin system in hypertensive pathophysiology.

Authors:  Jagdish N Sharma
Journal:  Inflammopharmacology       Date:  2012-04-17       Impact factor: 4.473

4.  Cleavage activation of human-adapted influenza virus subtypes by kallikrein-related peptidases 5 and 12.

Authors:  Brian S Hamilton; Gary R Whittaker
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

5.  KLK1 and ZG16B proteins and arginine-proline metabolism identified as novel targets to monitor atherosclerosis, acute coronary syndrome and recovery.

Authors:  Marta Martin-Lorenzo; Irene Zubiri; Aroa S Maroto; Laura Gonzalez-Calero; Maria Posada-Ayala; Fernando de la Cuesta; Laura Mourino-Alvarez; Luis F Lopez-Almodovar; Eva Calvo-Bonacho; Luis M Ruilope; Luis R Padial; Maria G Barderas; Fernando Vivanco; Gloria Alvarez-Llamas
Journal:  Metabolomics       Date:  2014-12-14       Impact factor: 4.290

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.